- Home
- FSP vs MOLN Comparison
FSP vs MOLN Comparison
Compare FSP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- MOLN
- Stock Information
- Founded
- FSP 1981
- MOLN 2004
- Country
- FSP United States
- MOLN Switzerland
- Employees
- FSP N/A
- MOLN N/A
- Industry
- FSP Real Estate Investment Trusts
- MOLN
- Sector
- FSP Real Estate
- MOLN
- Exchange
- FSP Nasdaq
- MOLN Nasdaq
- Market Cap
- FSP 165.9M
- MOLN 142.5M
- IPO Year
- FSP N/A
- MOLN 2021
- Fundamental
- Price
- FSP $1.19
- MOLN $4.16
- Analyst Decision
- FSP
- MOLN Hold
- Analyst Count
- FSP 0
- MOLN 1
- Target Price
- FSP N/A
- MOLN $4.00
- AVG Volume (30 Days)
- FSP 756.8K
- MOLN 6.5K
- Earning Date
- FSP 10-28-2025
- MOLN 10-30-2025
- Dividend Yield
- FSP 3.31%
- MOLN N/A
- EPS Growth
- FSP N/A
- MOLN N/A
- EPS
- FSP N/A
- MOLN N/A
- Revenue
- FSP $109,497,000.00
- MOLN N/A
- Revenue This Year
- FSP $4.36
- MOLN N/A
- Revenue Next Year
- FSP $0.81
- MOLN $1,000.00
- P/E Ratio
- FSP N/A
- MOLN N/A
- Revenue Growth
- FSP N/A
- MOLN N/A
- 52 Week Low
- FSP $1.18
- MOLN $3.36
- 52 Week High
- FSP $2.21
- MOLN $6.24
- Technical
- Relative Strength Index (RSI)
- FSP 19.42
- MOLN 62.47
- Support Level
- FSP $1.39
- MOLN $3.63
- Resistance Level
- FSP $1.42
- MOLN $4.72
- Average True Range (ATR)
- FSP 0.05
- MOLN 0.17
- MACD
- FSP -0.02
- MOLN 0.03
- Stochastic Oscillator
- FSP 1.67
- MOLN 52.94
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.